Human Evidence is a recurring topic in our peptide coverage. This hub collects every article tagged Human Evidence, newest first, each evidence-graded and tied to real, verifiable sources.
A clinical monograph on DSIP (delta sleep-inducing peptide / emideltide) — the endogenous nonapeptide marketed for sleep, withdrawal and pain. Thin, dated human data, an unidentified receptor, and a pivotal 2026 FDA compounding review.
A clinical monograph on Argireline — the 'topical Botox' peptide. Modest human evidence (Grade B), a real SNAP-25 mechanism, and a delivery problem that undercuts the marketing.
Human Evidence is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Human Evidence, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.